- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Clarence Moore: Luspatercept Is a Positive Step Forward in Beta Thalassemia
Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discusses a new treatment option for beta thalassemia.
Transcript
What are the unmet needs for patients with beta thalassemia? What more needs to be done in terms of therapy options?
I think we are moving in the right direction. Luspatercept [Reblozyl] was FDA approved within the past year or so. So, I think we're moving right in the right direction. I know, historically, there hadn't been any real movement in the disease state itself. Having some form of medication to decrease blood transfusions in that patient population, I think, is huge. I think we're heading in the right direction. I know we'd always like to have more medications, but I think with the movements we're seeing right now, we're doing well.
In November 2019, the FDA approved Reblozyl as a treatment option for anemia in transfusion dependent patients. What are the benefits of having this additional therapy available?
So, having that additional therapy I think is great because to be able to actually decrease the amount of infusions that those patients potentially [need]. And that decreased amount required infusions changes the landscape of essentially what we've historically done in the beta thalassemia disease setting.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria
April 15th 2025Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Read More
